Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
NCT07525219 Suzetrigine Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07525219 Suzetrigine Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07525219 clinical trial report covering Suzetrigine, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20261303 Pembrolizumab KRAS G12C mutant Non-small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20261303 Pembrolizumab KRAS G12C mutant Non-small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
CTR20261303 clinical trial report covering Pembrolizumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
JPRN-jRCT2031260049 Teriparatide Acetate( Asahi Kasei Pharma) Osteoporosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
JPRN-jRCT2031260049 Teriparatide Acetate( Asahi Kasei Pharma) Osteoporosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
JPRN-jRCT2031260049 clinical trial report covering Teriparatide Acetate( Asahi Kasei Pharma), Phase 3, endpoints, sponsor, geography, readout timing and de
Read →
NCT07528209 Oxaliplatin Locally Advanced Rectal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07528209 Oxaliplatin Locally Advanced Rectal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07528209 clinical trial report covering Oxaliplatin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07528716 Trastuzumab Rezetecan Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07528716 Trastuzumab Rezetecan Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07528716 clinical trial report covering Trastuzumab Rezetecan, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20261025 Lofacimig Thromboembolism Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20261025 Lofacimig Thromboembolism Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
CTR20261025 clinical trial report covering Lofacimig, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07528027 Safiglipron Hypertension Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07528027 Safiglipron Hypertension Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07528027 clinical trial report covering Safiglipron, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07529262 Aspirin Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07529262 Aspirin Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07529262 clinical trial report covering Aspirin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07526974 Resveratrol/Curcumin Subcutaneous fat disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07526974 Resveratrol/Curcumin Subcutaneous fat disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07526974 clinical trial report covering Resveratrol/Curcumin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07526987 Minocycline Hydrochloride Acute Ischemic Stroke Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07526987 Minocycline Hydrochloride Acute Ischemic Stroke Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07526987 clinical trial report covering Minocycline Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07529977 Minoxidil Androgenetic Alopecia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07529977 Minoxidil Androgenetic Alopecia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07529977 clinical trial report covering Minoxidil, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20261373 Recombinant Zoster Vaccine(CHO Cell)(Kangtai) Herpes Zoster Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20261373 Recombinant Zoster Vaccine(CHO Cell)(Kangtai) Herpes Zoster Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
CTR20261373 clinical trial report covering Recombinant Zoster Vaccine(CHO Cell)(Kangtai), Phase 3, endpoints, sponsor, geography, readout timing and develo
Read →